We are live on ! Find out more
RLMD icon

Relmada Therapeutics

83 hedge funds and large institutions have $56.4M invested in Relmada Therapeutics in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 20

4.55% less ownership

Funds ownership: 49.8% → 45.25% (-4.6%)

5% less funds holding

Funds holding: 87 → 83 (-4)

42% less capital inflows, than outflows

Capital inflows: $6.6M | Capital outflows: $11.3M

56% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 16

79% less call options, than puts

Call options by funds: $296K | Put options by funds: $1.41M

Holders
83
Holders Change
-4
Holders Change %
-4.6%
% of All Funds
1.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
25
Reduced
20
Closed
16
Calls
$296​K
Puts
$1.41​M
Net Calls
-⁠$1.12​M
Net Calls Change
-⁠$342​K

RLMD Hedge Fund Activity: Q4 2023 in Review

83 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2023, worth a combined $56.4M — up 25% from $45M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RLMD and 7 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 25 added.

The largest buyer was Opaleye Management, adding an estimated $2.51M. The largest seller was RTW Investments, exiting entirely with an estimated $6.4M sold.

  • 83 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2023, down from 87 in Q3 2023.
  • Funds reported $56.4M of Relmada Therapeutics stock for Q4 2023, up 25% quarter-over-quarter.
  • 7 funds opened new Relmada Therapeutics positions in Q4 2023 and 16 closed out, a net change of -9 holders.
  • The largest Relmada Therapeutics buyer in Q4 2023 was Opaleye Management, an estimated $2.51M added.
  • The largest Relmada Therapeutics seller in Q4 2023 was RTW Investments, an estimated $6.4M sold.

Based on aggregated 13F filings for Q4 2023.